Sign In
Buy ERAS
$18.15
-0.530 (-2.84%)
At Close: Jul 31, 2026
NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Erasca, Inc. (NASDAQ: ERAS) between January 14, 2025 and April
ERAS Shareholder Alert: Erasca, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky
10:07am, Wednesday, 15'th Jul 2026
Erasca Allegedly Raised $258.8 Million Through a Shelf Registration Statement While Concealing Patent Infringement Risk and Improper Preclinical Comparisons for Its Lead Drug Candidate NEW YORK, July
NEW YORK and NEW ORLEANS, July 14, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Erasca
ERAS INVESTOR DEADLINE: Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - HBSS
09:44pm, Tuesday, 14'th Jul 2026
SAN FRANCISCO, July 14, 2026 /PRNewswire/ -- Erasca, Inc. (NASDAQ: ERAS) faces a securities class action after the stock tanked $9.25 (-48%) on news that Revolution Medicines (RevMed) accused Erasca o
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ: ERAS). Such inves
Erasca Unveils Updated Cancer Candidate Progress, Maps Path Toward Pivotal Cancer Trials
02:33pm, Tuesday, 14'th Jul 2026
Erasca Inc. (NASDAQ:ERAS) reported updated preliminary Phase 1 data for its investigational pan-RAS molecular glue ERAS-0015, citing encouraging early activity in RAS-mutant solid tumors while outlini
New York, New York--(Newsfile Corp. - July 14, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Erasca, Inc. (NASDAQ: ERAS) between January 14, 20
Bronstein, Gewirtz & Grossman LLC Urges Erasca, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
12:00pm, Tuesday, 14'th Jul 2026
New York, New York--(Newsfile Corp. - July 14, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed agains
Erasca, Inc. (ERAS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
12:00pm, Tuesday, 14'th Jul 2026
LOS ANGELES, July 14, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Erasca, In
NEW YORK, July 14, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Erasca, Inc. (NASDAQ: ERAS). Shareholders who purchased shares of ERAS during the class period
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 10, 2026 in Erasca, Inc. Lawsuit - ERAS
09:56am, Tuesday, 14'th Jul 2026
Important Information Regarding Section 20(a) Individual Liability Claims: Erasca's CEO and CFO Allegedly Certified Misleading Statements About ERAS-0015 While the Company Raised $258.8 Million From I
ERASCA, INC. SECURITIES FRAUD NOTICE: Berger Montague Informs Erasca, Inc. (ERAS) Investors of a Securities Fraud Lawsuit
09:21am, Tuesday, 14'th Jul 2026
Philadelphia, Pennsylvania--(Newsfile Corp. - July 14, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Erasca, Inc. (NASDAQ: ERAS) ("Erasca" or the "C
Erasca Announces Pricing of Upsized Public Offering of Common Stock
11:10pm, Monday, 13'th Jul 2026
SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for p
SAN FRANCISCO, July 13, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ: ERAS) faces a securities class action after the stock tanked $9.25 (-48%) on news that Revolution Medicines (RevMed) accused Eras
Erasca Announces Proposed Public Offering of $500 Million of Common Stock
04:19pm, Monday, 13'th Jul 2026
SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for p
